SCHEMBL7872533

SCHEMBL7872533

O=[N+]([O-])c1cc(Br)c(Cl)cc1F

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.46
ATM Q13315 1/20 0.46
ALDH1A1 P00352 3/20 0.44
HIF1A Q16665 2/20 0.44
VCAM1 P19320 3/20 0.42
MAPT P10636 2/20 0.41
PKM P14618 1/20 0.41
MAPK1 P28482 3/20 0.41
TSHR P16473 2/20 0.41
ESPL1 Q14674 1/20 0.41
PDE7A Q13946 1/20 0.41
CYP3A4 P08684 2/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
TXNRD1 Q16881 1/20 0.39
TXNRD3 Q86VQ6 1/20 0.39
TXNRD2 Q9NNW7 1/20 0.39
CTSB P07858 1/20 0.39
GPR35 Q9HC97 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31702150 0.92 TDP1 (0.46) TDP1ATMALDH1A1HIF1AVCAM1
SCHEMBL2479797 0.92 TDP1 (0.46) TDP1ATMALDH1A1HIF1AVCAM1
SCHEMBL2596256 0.87 TDP1 (0.42) TDP1ATMALDH1A1HIF1AVCAM1
SCHEMBL32679322 0.85 TDP1 (0.46) TDP1ATMALDH1A1HIF1AVCAM1
SCHEMBL18112975 0.85 TDP1 (0.46) TDP1ATMALDH1A1HIF1AVCAM1
SCHEMBL18905090 0.84 TDP1 (0.52) TDP1ATMALDH1A1HIF1AVCAM1
SCHEMBL14578462 0.84 TDP1 (0.52) TDP1ATMALDH1A1HIF1AVCAM1
SCHEMBL29580289 0.84 TDP1 (0.52) TDP1ATMALDH1A1HIF1AVCAM1
SCHEMBL123793 0.84 TDP1 (0.52) TDP1ATMALDH1A1HIF1AVCAM1
SCHEMBL8967138 0.82 TDP1 (0.50) TDP1ATMALDH1A1HIF1AVCAM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-62114941-A None JP disclosed
US-12485169-B2 Compounds Grey Wolf Therapeutics Limited (GB) 2025-12-02 US disclosed
US-20250333399-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES KHORA SPV 1 LLC (US) 2025-10-30 US disclosed
US-20250223300-A1 MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BETTA PHARMACEUTICALS CO LTD (CN) 2025-07-10 US disclosed
US-12331039-B2 Inhibitors of fibroblast growth factor receptor kinases KHORA SPV 1, LLC (US) 2025-06-17 US disclosed
EP-4559920-A1 MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Betta Pharmaceuticals Co., Ltd (CN) 2025-05-28 EP disclosed
CN-120025279-A Compounds capable of modulating endoplasmic reticulum aminopeptidase 1 格雷沃尔夫治疗有限公司 2025-05-23 CN disclosed
CN-119998278-A Compounds and uses thereof 福宏治疗公司 2025-05-13 CN disclosed
US-12264147-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding Propellon Therapeutics Inc. (CA) 2025-04-01 US disclosed
EP-4522278-A1 BENZOYPARAZINE PYRAZINES ANE THEIR USES Foghorn Therapeutics Inc. (US) 2025-03-19 EP disclosed
US-9221816-B2 2-oxo-2,3-dihydro-indoles for the treatment of CNS disorders HOFFMANN LA-ROCHE INC. (US) 2015-12-29 US disclosed
CN-105164112-A Amide compound and preparation method, pharmaceutical composition and application thereof SHANGHAI INST MATERIA MEDICA 2015-12-16 CN disclosed
US-20150284386-A1 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS HOFFMANN-LA ROCHE INC. (US) 2015-10-08 US disclosed
EP-2895476-A1 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS F. Hoffmann-La Roche AG (CH) 2015-07-22 EP disclosed
US-20140319507-A1 Organic Electroluminescent Element, Material for Organic Electroluminescent Element, Light Emitting Device, Display Device and Lighting Device Each Using Said Element, and Compound Used for Said Element UDC IRELAND LIMITED (IE) 2014-10-30 US disclosed
WO-2014040969-A1 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2014-03-20 WO disclosed
CN-1244542-C Aromatic amine derivatives having NOS inhibitory effect CHUGAI PHARMACEUTICAL CO LTD (JP) 2006-03-08 CN disclosed
US-6331553-B1 INHIBITORS OF NITRIC OXIDE SYNTHASE; TREATING CEREBROVASCULAR DISEASES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2001-12-18 US disclosed
EP-0949242-A1 AROMATIC AMINE DERIVATIVES HAVING NOS INHIBITORY EFFECT Chugai Seiyaku Kabushiki Kaisha (JP) 1999-10-13 EP disclosed
JP-S62114941-A 5-BROMO-4-CHLORO-2-FLUOROANILINE AND PRODUCTION THEREOF SUMITOMO CHEM CO LTD 1987-05-26 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12264147-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding WDR5, WDR82, WDR1 TDP1 3050/4885ATM 3350/4885ALDH1A1 3236/4885
US-12331039-B2 Inhibitors of fibroblast growth factor receptor kinases FGFR1, FGFR2, FGFR3 TDP1 2063/4885ATM 484/4885ALDH1A1 2169/4885
US-20250333399-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES FGFR1, FGFR2, FGFR3 TDP1 2063/4885ATM 484/4885ALDH1A1 2169/4885
US-12485169-B2 Compounds SLC10A1, VHL, CFTR TDP1 1403/4885ATM 991/4885ALDH1A1 276/4885
US-20250223300-A1 MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF EGFR, ERBB3, ERBB2 TDP1 4371/4885ATM 723/4885ALDH1A1 3526/4885
US-20150284386-A1 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS HCRTR2, TPH2, CNR2 TDP1 2939/4885ATM 4565/4885ALDH1A1 1145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.